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Understanding mechanisms that contribute to the regression
of glomerulosclerosis is important for developing new
strategies to treat chronic kidney disease. We reported that
transient high-dose treatment with an angiotensin receptor
blocker causes regression of renal arteriolar hypertrophy and
hypertension in spontaneously hypertensive rats. To extend
those findings to another form of kidney disease, we examined
the short- and long-term effects of transient high-dose
angiotensin receptor blocker treatment in a mouse model
of adriamycin-induced glomerulosclerosis. A 2-week course
of candesartan caused a dose-dependent regression of
established glomerulosclerotic lesions sustained for over
6 months following cessation of treatment. Highly sensitive
in situ zymography and activity assays showed that
glomerular matrix metalloproteinase (MMP)-2 activity was
increased after high-dose angiotensin blocker therapy.
Treatment of cultured podocytes with candesartan resulted
in an increase in MMP-2 activity. The regression of
glomerulosclerosis was partially attenuated in mice
pretreated with the MMP inhibitor doxycycline, as well as
in MMP-2 knockout mice. Our results suggest that transient
high-dose angiotensin receptor blocker treatment effectively
induced sustained regression of glomerulosclerosis by a
mechanism mediated, in part, by changes in MMP-2 activity.
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It has been reported that the prevalence of chronic kidney
disease is increasing, and may be as high as 10–13%
throughout the world.1 Regardless of the initial etiology,
progressive kidney disease shares several common patholo-
gical features, one of which is the development of glomerular
scarring or glomerulosclerosis.
Glomerulosclerosis occurs because of the excessive deposi-
tion of components of the extracellular matrix (ECM) in
the glomeruli, resulting in changes in glomerular integrity
and albuminuria. This process is triggered by increased
synthesis of ECM components, and decreased degradation of
ECM components, resulting in net accumulation of ECM in
the sclerotic lesions.2
Although it has been widely assumed that established
sclerosis is irreversible and usually progressive, recent studies
have challenged this concept, and focused on developing
new therapies to cause regression or repair of established
glomerulosclerosis.2,3 Direct evidence that regression of
established glomerular injury may be observed in humans
was shown by Fioretto et al.,4 who showed that the changes of
diabetic nephropathy were reversed after pancreatic trans-
plantation in patients with diabetes. Recent studies have
suggested that treatment with a renin–angiotensin system
(RAS) inhibitor may be effective in causing various degrees
of regression of glomerular lesions in animal models.5–7
Recently, we reported that transient treatment with an
angiotensin receptor blocker (ARB) at a high dose causes
regression of renal arteriolar hypertrophy in spontaneously
hypertensive rats, resulting in a sustained decrease in
hypertension.8 These results prompted us to undertake
the first clinical study to examine whether regression of
hypertension is feasible in humans (the STAR CAST study).9
Because of the importance of developing methods of
glomerulosclerosis regression, our aims in this study were,
firstly, to examine the effects of treatment with different
doses of ARB on established lesions of glomerulosclerosis in
the adriamycin nephropathy model.10,11 Secondly, we exam-
ined whether the regression was sustained after cessation
of the ARB treatment. The third aim was to examine the
involvement of matrix metalloproteinase-2 (MMP-2) in the
mechanism of glomerulosclerosis regression in vitro and
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in vivo, using both a nonspecific MMP inhibitor (doxycy-
cline), and knockout (KO) mice with targeted deletion
of MMP-2.
RESULTS
Effects of transient treatment with high-dose ARB in
adriamycin-induced glomerulosclerosis
The effects of injection of FVB/NJ mice with adriamycin
(18 mg/kg intravenous (i.v.)) are shown in Figure 1a and b.
As in our previous studies using FVB/NJ and C57BL/6
mice,11 adriamycin injection caused the development of
robust albuminuria and glomerulosclerosis that reached
a plateau at 8 weeks after the adriamycin injection, and
therefore the subsequent ARB treatments were started after
8 weeks (Figure 1c). As shown in Figure 1d, treatment
with ARB for 2 weeks caused a dose-dependent reduction in
albuminuria. Quantitative assessment of the periodic acid-
Schiff (PAS)-positive stained glomerulosclerosis area revealed
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Figure 1 | Effects of high-dose angiotensin receptor blocker (ARB) on regression of albuminuria and glomerulosclerosis.
(a, b) Characterization of adriamycin (ADM)-induced albuminuria and glomerulosclerosis. (a) Time course of albuminuria development
after ADM injection. (b) Time course of glomerulosclerosis development after ADM injection. (c–f) Effects of different doses of ARB on
regression of albuminuria and glomerulosclerosis in adriamycin-treated mice. At 8 weeks after ADM injection, candesartan (Cand) was
administered for 2 weeks, and mice were killed at the end of Cand treatment. (c) Experimental protocol. (d) Effects of transient treatment
with different doses of ARB on albuminuria. (e) Representative photomicrographs of glomerular histology. (f) Effects of transient treatment
with different doses of ARB on glomerulosclerosis area. (g) Effects on tail-cuff systolic blood pressure. *Po0.05, **Po0.01 vs ADM();
þþPo0.01 vs ADM(þ ) Cand 0; #Po0.05 between the respective groups. PAS, periodic acid-Schiff.
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a significant reduction in the mice that had been treated with
the higher doses of ARB (candesartan 5 and 50 mg/kg/day),
signifying regression of established glomerulosclerosis (Fig-
ure 1e and f). No significant differences in the systolic blood
pressures were detectable in the different groups, within the
limitation of the indirect tail-cuff method (Figure 1g).
Effects of transient treatment with high-dose ARB on
glomerular collagen deposition and MMP activities
The effects of the ARB treatments on total and type IV
collagen deposition were assessed by Picro-sirius red staining
and type IV collagen immunofluorescence, respectively.
As shown in Figure 2a and b, the treatment with ARB caused
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Figure 2 | Effects of different doses of angiotensin receptor blocker (ARB) on glomerular collagen staining and matrix
metalloproteinase (MMP) activities in adriamycin-treated mice. (a) Representative photomicrographs of Picro-sirius red staining
and type IV collagen immunofluorescence staining. Quantification of (b) Picro-sirius red-stained area and type IV collagen immunostained
area. (c) Foot process effacement area. (d) Representative photomicrographs of in situ zymography of MMP-2 and MMP-9 activities.
(e) Immunofluorescence staining of MMP-2 and MMP-9 expression. (f) Quantification of glomerular MMP-2 and MMP-9 activities by in situ
zymography. (g) Direct assays of glomerular MMP-2 and MMP-9 activities. Abbreviations as in Figure 1. *Po0.05, **Po0.01 vs ADM();
þPo0.05, þþPo0.01 vs ADM(þ ) candesartan (Cand) 0.
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a reduction in the Picro-sirius red-stained area and type IV
collagen immunostained areas, which was not statistically
significant with the normal dose of ARB (1 mg/kg/day),
but clearly was observed with the higher doses of ARB
(candesartan 5 and 50 mg/kg/day). Quantification of the foot
process effacement areas revealed a small decrease with the
higher doses of ARB, but the results did not attain statistical
significance (Figure 2c). To examine the potential mechan-
isms of these changes, glomerular MMP-2 and MMP-9
activities were examined by highly sensitive in situ zymo-
graphy. It was found that glomerular MMP-2 activity was
increased by the treatment with ARB, whereas MMP-9
activity was not significantly changed (Figure 2d and f).
Similar results were found by immunofluorescence staining,
and direct assays on MMP-2 and MMP-9 activities in isolated
glomeruli, confirming that MMP-2 expression and activities
were increased in the mice treated with high-dose ARB
(Figure 2e and g). Because rodents lack the MMP-1 gene, we
also examined changes in activity of the rodent collagenase
MMP-13, and found that ARB caused a decrease rather
than an increase in MMP-13 activity in the glomeruli
(see Supplementary Figure S1).
Long-term effects of high-dose ARB on albuminuria and
glomerulosclerosis
We next examined the long-term effects of transient
high-dose ARB treatment on albuminuria and glomerulo-
sclerosis (Figure 3a). Of interest, the significant reductions
in albuminuria and glomerulosclerosis were found to be
sustained 6 months after the ARB treatment was discon-
tinued (Figure 3b–d). The changes in glomerular MMP-2
activity assessed by in situ zymography are shown in Figure
3e. MMP-2 activity, which was transiently increased during
the ARB treatment period, was found to decline to baseline
after the ARB treatment was discontinued.
Effects of ARB on secretion of MMP-2 by cultured
podocytes and mesangial cells
The results of the in situ zymography and immunofluores-
cence suggested that the increase in MMP-2 expression and
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Figure 3 | Long-term effects of treatment with high-dose angiotensin receptor blocker (ARB) on albuminuria and glomerulosclerosis
in adriamycin-treated mice. Candesartan (Cand, 50mg/kg/day) was administered for 2 weeks, starting 8 weeks after ADM injection.
(a) Experimental protocol. (b) Time course of effects on albuminuria. (c) Representative photomicrographs of glomerular histology.
(d) Time course of effects on glomerulosclerosis area. (e) Time course of effects on glomerular matrix metalloproteinase (MMP)-2 and
MMP-9 activities. Abbreviations as in Figure 1. **Po0.01 vs ADM(); þPo0.05, þþPo0.01 vs ADM(þ ) Cand 0.
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activity was observed predominantly in glomerular podocytes
rather than mesangial cells. To examine this possibility, we
performed in vitro studies on cultured podocytes and
mesangial cells. Addition of ARB to the media of cultured
podocytes resulted in a small (1.5- to 2-fold) but significant
increase in MMP-2 activity in the medium (Figure 4a).
MMP-9 activities in both the medium and the cellular
fractions were below the limit of assay sensitivity. The effects
of ARB were dose dependent, reaching a maximum at
0.1 mmol/l (Figure 4b). A significant increase in MMP-2
secretion was also observed in podocytes treated with a
peptide Ang II antagonist (saralasin), or an angiotensin-
converting enzyme (ACE) inhibitor (captopril), whereas
treatment with Ang II caused a tendency to decreased
MMP-2 activity (Figure 4c). In contrast, none of these agents
caused a change in MMP-2 activities in the medium of
cultured rat mesangial cells (Figure 4d–f).
Effects of doxycycline pretreatment on high-dose
ARB-induced regression of glomerulosclerosis
To examine the potential role of the observed changes in
MMP activity in the effects of high-dose ARB, the effects of
pretreatment with the nonspecific MMP inhibitor doxycy-
cline were examined (Figure 5a). It was found that the effects
of ARB on albuminuria and glomerulosclerosis were partially
attenuated in mice pretreated with doxycycline when
compared with untreated mice, suggesting the possibility
that inhibition of the upregulated MMP-2 activity by
doxycycline caused an attenuation of the ARB-induced
effects (Figure 5b–d).
Effects of MMP-2 deletion on high-dose ARB-induced
regression of glomerulosclerosis
To further characterize the role of MMP-2 in the observed
effects of high-dose ARB, experiments were next performed
using MMP-2-deleted (MMP-2 KO) mice (Figure 5e). Similar
to the doxycycline experiments, the effects of ARB to reduce
albuminuria and glomerulosclerosis were attenuated, but not
completely inhibited, in the MMP-2 KO mice when
compared with their wild-type controls, suggesting the
involvement of MMP-2 in the observed actions of high-dose
ARB (Figure 5f–h).
DISCUSSION
The main findings of this study were as follows: (1) transient
treatment for 2 weeks with the ARB candesartan caused a
regression of established glomerulosclerosis that was clearly
evident with the high doses of ARB; (2) the regression of
glomerulosclerosis was sustained 6 months after cessation of
all treatments; (3) ARB treatment caused a dose-dependent
increase in glomerular MMP-2 activity and decrease in type
IV collagen accumulation; (4) MMP-2 secretion by podocytes
in vitro was increased in the presence of ARB; and (5) the
ARB-induced regression of glomerulosclerosis was attenuated
by pretreatment with the MMP inhibitor doxycycline, as well
as in mice with targeted deletion of the MMP-2 gene.
Since Fioretto et al.4 showed that the lesions of diabetic
nephropathy may be reversed by pancreas transplantation,
new methods to cause regression of glomerulosclerosis are
receiving increasing attention. Indeed, understanding the
mechanisms of reversal of glomerulosclerosis may be an
important step for designing new treatments to attenuate the
growth in the increasing number of patients with chronic
kidney disease.
In this study, we analyzed the ability of high-dose
treatment with an ARB to cause regression of adriamycin-
induced glomerulosclerosis. Although adriamycin injury
was originally described to cause nephrosis, glomerulosclero-
sis, and interstitial inflammation in Balb/c mice even at low
doses (10 mg/kg),12 we have found in previous studies that
treatment of FVB/NJ or C57BL/6 mice with a single high
dose (18 mg/kg) of adriamycin caused a highly reproducible
glomerulosclerosis without the development of detectable
interstitial inflammation or fibrosis.11 The glomerulosclerosis
included both mesangial expansion and obliteration of
capillary lumens by ECM. It has been reported that sclerotic
lesions contain large amounts of type IV collagen, which is
usually expressed predominantly in the basement membrane
in normal glomeruli;13 therefore, the degree of glomerulo-
sclerosis was assessed by the examination of not only total
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Figure 4 | In vitro studies. Effects of angiotensin receptor blocker
(ARB) treatment on matrix metalloproteinase-2 (MMP-2) secretion
by cultured podocytes (a–c) and mesangial cells (d–f) in vitro. (a, d)
Time course of effects of 106mol/l candesartan (Cand) treatment
on MMP-2 secretion. (b, e) Dose dependency of effects of Cand
treatment for 6 days on MMP-2 secretion. (c, f) Effects of
treatment with other renin–angiotensin system (RAS) inhibitors
for 6 days on podocyte MMP-2 secretion. AII, treated with
angiotensin II (106mol/l); Cand, treated with candesartan
(106mol/l); Capto, treated with captopril (106mol/l); Sar,
treated with saralasin (106mol/l); Veh, vehicle; *Po0.05 vs Veh;
þPo0.05 between the respective groups.
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Figure 5 | Effects of doxycycline pretreatment or matrix metalloproteinase-2 (MMP-2) deletion (MMP-2 knockout (KO)) on
high-dose angiotensin receptor blocker (ARB)-induced regression of albuminuria and glomerulosclerosis in adriamycin-treated mice.
(a) Experimental protocol of doxycycline studies. (b) Effects of doxycycline pretreatment on high-dose ARB-induced regression of albuminuria.
(c) Representative photomicrographs of glomerular histology in the doxycycline pretreated and untreated groups. (d) Effects of doxycycline
pretreatment on high-dose ARB-induced regression of glomerulosclerosis area and collagen deposition. (e) Experimental protocol of MMP-2 KO
studies. (f) Effects of MMP-2 deletion on high-dose ARB-induced regression of albuminuria. (g) Representative photomicrographs of glomerular
histology in the wild-type (WT) and MMP-2 KO groups. (h) Effects of MMP-2 deletion on high-dose ARB-induced regression of glomerulosclerosis
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collagen deposition (assessed by Picro-Sirius red staining),
but also type IV collagen immunostaining.
ARB treatment of these mice with established glomerular
scarring caused a significant reversal of glomerulosclerosis
together with a decrease in total collagen deposition and
type IV collagen deposition. Interestingly, the regression of
glomerulosclerosis was unremarkable with a widely used
‘standard’ dose of candesartan in rodents (1 mg/kg/day),14,15
but was clearly observed with the high doses of ARB (5 and
50 mg/kg/day). Moreover, ARB treatment caused a dose-
dependent increase in glomerular MMP-2 activity, suggesting
the possibility that increased expression of MMP-2 may
contribute to the regression of glomerulosclerosis observed in
the high-dose-treated groups.
The MMPs constitute a multigene family of zinc- and
calcium-dependent endopeptidases that have a major role in
the degradation of collagen and other ECM components.16–18
In this study, we found that the high-dose ARB-induced
regression of glomerulosclerosis was partially attenuated in
mice pretreated with the MMP inhibitor doxycycline, as well
as in mice with targeted deletion of the MMP-2 gene,
suggesting that the ARB-induced increase in MMP-2 activity
contributes to the observed regression of glomerulosclerosis
and type IV collagen deposition.
MMP-2 is an MMP that is involved in the cleavage of
multiple ECM components, including type IV collagen.16,17
It is known to be a secreted protein that may be prepared
from the conditioned media of cultured fibroblasts. In
contrast to gelatinase B (MMP-9), MMP-2 is not highly
expressed in normal or diseased glomeruli.19 However, it has
been shown that renal MMP-2 expression and activity are
upregulated by ACE inhibitors in rats with diabetes.20,21
Moreover, Turkay et al.22 reported that the ACE inhibitor
enalapril also increased hepatic MMP-2 expression in rats
with experimental hepatic fibrogenesis, whereas Westermann
et al.23 showed that the ARB irbesartan increased MMP-2
activity in the hearts of mice with cardiomyopathy, suggest-
ing that the RAS has a key role in regulation of MMP-2
expression in the kidney and other tissues.
In our study, the results of highly sensitive in situ
zymography and immunofluorescence suggested that
MMP-2 might be upregulated in glomerular podocytes, but
this could not be determined accurately because of the
relatively low expression of MMP-2 protein. Therefore, to
further characterize the mechanisms of the ARB-induced
increase in glomerular MMP-2 activity, we examined the
effects of ARB treatment in cultured podocytes. These
experiments revealed that ARB treatment of podocytes
resulted in a dose-dependent increase in MMP-2 activity in
the supernatant. Podocytes are known to express components
of the RAS, including renin, angiotensinogen, angiotensin-
converting enzyme, and AT1 and AT2 receptors.24,26 More-
over, functional expression of the RAS has been documented
in both mouse and human podocytes.25,26 To examine the
possibility that the effects of ARB were mediated through
inhibition of the RAS, further studies were performed using
an ACE inhibitor, and a non-peptide Ang II antagonist
(Saralasin). The use of these different RAS inhibitors yielded
similar results, suggesting that the effects of ARB were
mediated by inhibition of the intrinsic RAS in podocytes.
Stacy et al.27 reported similar findings in fibroblasts, namely
that addition of losartan to primary cultures of cardiac
fibroblasts causes a dose-dependent increase in MMP-2
activity, suggesting that similar mechanisms may be involved
in different cell types.
It was observed in vitro that the increase in MMP-2
activity was greatest at the high doses of candesartan
(40.1 mmol/l), whereas maximum plasma concentrations
in humans administered a standard dose of candesartan are
below the nanomolar range.28 Assuming that local (glome-
rular) concentrations of ARB will be greatest with the high
doses of ARB, these in vitro results are consistent with the in
vivo observation that the glomerulosclerosis regression was
maximal with the high doses of ARB.
In humans, it is known that MMP-1 (collagenase-1) also
has a major role in the breakdown of collagens, in particular
type I and type III collagen. It has been reported that rodents
lack the human MMP-1 gene, and MMP-13 (collagenase-3) is
the main collagenase in mice.29,30 We therefore examined the
possibility that MMP-13 may also contribute to the observed
changes, but found that ARB treatment did not increase
glomerular MMP-13 activity, but rather decreased its activity,
suggesting that increased MMP-13 activity did not contribute
to the observed regression of glomerulosclerosis.
It is interesting that neither inhibition of MMP nor
deletion of MMP-2 completely abolished the effects of
high-dose ARB, suggesting that other mechanisms may be
involved. One possibility is the contribution of other
proteases such as the serine protease PAI-1 (plasminogen
activator inhibitor-1).5 It has been suggested that regenera-
tion of glomerular podocyte function may also have a role in
regression of glomerulosclerosis by RAS inhibitors.7
Although we were unable to detect a significant decrease in
podocyte foot process effacement area after ARB treatment,
improvement of other parameters of podocyte function
cannot be ruled out. Such mechanisms could contribute
to the sustained reduction of albuminuria observed in
this study.
It should be stressed that the effects of ARB on regression
may differ widely in different animal models. In particular, the
effects of ARB on regression were less marked in the 5/6
nephrectomy model.5 This may be because the adriamycin
model relies on a single (acute) injury to the glomeruli,
whereas the injury in the 5/6 nephrectomy model occurs
continuously, probably as a result of chronic glomerular
hypertension. In this study, we found that MMP-2 activity
decreased to baseline after the ARB treatment was discon-
tinued. The transient increase in MMP-2 was probably
sufficient to permanently reverse the glomerulosclerosis in this
adriamycin model, but its effect in other models are unclear.
Taken together, the results from different this and other
experimental studies,5,6 and from several clinical studies
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using different ARBs,31–33 suggest in common that high-dose
ARB treatment may have additional beneficial effects on the
kidney compared with standard doses. One potential reason
may be that standard doses of ARB do not fully suppress the
RAS in the kidneys. Another possibility is that mechanisms
unrelated to RAS inhibition may be involved, for example, an
antioxidant action independent of AT1 receptor blockade.34
Further studies are required to differentiate these possibi-
lities. The clinical implication is that the use of higher than
normal ARB doses may be necessary to obtain the optimum
benefit from these agents.
In conclusion, the results of this study suggest that
transient treatment with high-dose ARB causes sustained
regression of glomerulosclerosis in the adriamycin model, by
a mechanism mediated in part by changes in MMP-2 activity.
Because of the high prevalence of chronic kidney disease
throughout the world,1 these results may be important for
designing new strategies for the reversal of the process
of glomerulosclerosis, leading to improved treatments of
chronic kidney diseases.
MATERIALS AND METHODS
Animal treatment protocols
The studies were conducted using 10-week-old male FVB/NJ mice,
MMP-2 KO mice, and their wild-type littermates. FVB/NJ mice
were obtained commercially from Clea Japan (Tokyo, Japan).
MMP-2 KO mice, originally developed in the laboratory of
Dr Itohara, were obtained from the Riken Bioresource Center
(Ibaraki, Japan).35 Breeder mice were backcrossed five times into the
C57BL/6J genetic background. Control experiments for the KO mice
were performed using wild-type littermates obtained from mating of
heterozygous breeding pairs. Adriamycin was obtained from Kyowa
Hakko Kogyo, Tokyo, Japan, and was freshly dissolved in saline at a
concentration of 5 mg/ml immediately before injection. Candesartan
cilexetil (TCV-116) for in vivo experiments and candesartan
(CV-11974) for in vitro experiments were a kind gift from Takeda
Pharmaceutical (Tokyo, Japan). Other reagents were obtained
from Sigma-Aldrich (St Louis, MO, USA) unless otherwise stated.
All experiments were performed in accordance with the Animal
Experimentation Guidelines of the Keio University School of
Medicine.
Preliminary protocol: characterization of adriamycin-induced
albuminuria and glomerulosclerosis in FVB/NJ mice. FVB/NJ
mice were randomly divided into five groups (n¼ 5 per group) and
injected with adriamycin (18 mg/kg i.v.), as reported by us
previously for FVB/NJ and C57BL/6J mice.11 Albuminuria and
glomerulosclerosis were examined at 0, 2, 4, 8, and 12 weeks after
adriamycin injection.
Protocol 1: dose-dependency studies of high-dose ARB
treatment. FVB/NJ mice were randomly divided into six groups
as follows (n¼ 10 per group): group 1 was untreated, whereas the
other groups (2–6) were injected with adriamycin (18 mg/kg i.v.) to
induce glomerulosclerosis. Groups 1 and 2 were killed 8 weeks after
adriamycin injection. Groups 3, 4, 5, and 6 were treated for 2 weeks
(from 8 to 10 weeks after adriamycin injection) with the ARB
candesartan cilexetil dissolved in drinking water to deliver a dose of
0, 1, 5, and 50 mg/kg/day, respectively, as described previously,8,36
and were killed at the end of ARB treatment.
Protocol 2: time course studies of high-dose ARB treat-
ment. FVB/NJ mice were randomly divided into seven groups as
follows (n¼ 10 per group): group 1 was untreated and killed at
the same time as group 2. Groups 2, 3, 4, 5, 6, and 7 were injected
with adriamycin (18 mg/kg i.v.), treated with the ARB candesartan
cilexetil at a dose of 50 mg/kg/day for 2 weeks (from 8 to 10 weeks
after adriamycin injection), and then killed at 0, 1, 2, 4, 12, and
32 weeks after starting the ARB treatment, respectively.
Protocol 3: doxycycline studies. FVB/NJ mice were divided
into five groups as follows (n¼ 10 per group): mice in group 1 were
untreated; mice in groups 2–5 were injected with adriamycin
(18 mg/kg i.v.); and mice in groups 4 and 5 were treated with the
ARB candesartan cilexetil at a dose of 50 mg/kg/day for 2 weeks
(from 8 to 10 weeks after adriamycin injection), and then killed at
the end of ARB treatment. In addition, the mice in groups 3 and
5 were pretreated with doxycycline (60 mg/kg/day in drinking
water) from 3 days before the start of ARB treatment to the time
of killing.
Protocol 4: MMP-2 KO studies. MMP-2 KO mice and their
wild-type littermates were randomly divided into six groups as
follows (n¼ 8 per group): groups 1, 3, and 5 were wild-type mice
and groups 2, 4, and 6 were KO mice. Mice in groups 3–6 were
injected with adriamycin (18 mg/kg i.v.). Furthermore, groups
5 and 6 were treated with the ARB candesartan cilexetil at a dose
of 50 mg/kg/day for 2 weeks (from 8 to 10 weeks after adriamycin
injection), and then killed at the end of ARB treatment.
Biochemical studies and blood pressure measurement
Urine collections were performed in metabolic cages, and urine
albumin concentrations were determined by a direct compe-
titive enzyme-linked immunosorbent assay (Albuwell; Exocell,
Philadelphia, PA, USA). Systolic blood pressures were estimated
by indirect tail-cuff plethysmography using a Natsume KN-210
manometer (Natsume, Tokyo, Japan).
Isolation of glomeruli and assessment of glomerular MMP
activities
Glomeruli were obtained from the treated mice by injection of
iron oxide particles, followed by repeated sieving and magnetic
separation of glomeruli, as reported previously.37 Protein content
in the glomeruli were assessed by the Lowry method, and MMP-2
and MMP-9 activities were analyzed using the respective Biotrak
activity assay kits (Amersham International, Amersham, UK).
Histological studies
The kidneys were removed and fixed in 4% paraformaldehyde and
then embedded in paraffin blocks. Histological sections from the
mice kidneys were stained with PAS and Picro-Sirius red. Slides were
examined by light microscopy, and a quantitative assessment of the
PAS-positive area (as an index of glomerulosclerosis) and Picro-
Sirius red-stained area (as an index of collagen deposition) were
performed, as described by us previously,11,36 and expressed as the
percentage of the total glomerular area. Other kidney samples were
fresh frozen in optimal cutting temperature compound, and then
sectioned using a cryotome for analysis of type IV collagen, MMP-2,
and MMP-9 expression by immunofluorescence staining, and MMP
activity by in situ zymography. In some experiments, transmission
electron microscopy was performed on glutaraldehyde-fixed, epoxy-
embedded kidney samples, and podocyte foot process effacement
was determined by the method of Guo et al.38
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Immunofluorescence staining
Immunofluorescence staining of glomerular type IV collagen,
MMP-2, and MMP-9 expression was performed on the cryostat
sections using polyclonal anti-type IV collagen antibodies
(Chemicon-Millipore, Billerica, MA, USA), polyclonal anti-MMP-
2 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and
polyclonal anti-MMP-9 antibodies (Chemicon-Millipore), as de-
scribed previously.8,11 The anti-MMP-2 and anti-MMP-9 antibodies
recognize both the active and latent forms of MMP.
In situ zymography
High-resolution, high-sensitive zymography was performed as
reported by us previously,8,11 using the substrates DQ-collagen
IV and DQ-collagen I (Molecular Probes, Cambridge, UK) in the
presence or absence of specific MMP inhibitors.
In vitro studies
Human podocytes (kindly provided by Dr MA Saleem, Children’s and
Academic Renal Unit, University of Bristol, UK) were propagated and
differentiated as described previously.39 Rat mesangial cells were
cultured in RPMI and 10% fetal calf serum.40 Podocytes and mesangial
cells were stimulated with various concentrations (105 to 109 mol/l)
of candesartan (CV-11974, active metabolite of candesartan cilexetil),
or with Ang II (106 mol/l), [Sar1, Val5, Ala8]-Ang II (saralasin,
106 mol/l), or captopril (106 mol/l), and then MMP-2 and MMP-9
activities in the supernatant were analyzed using the respective Biotrak
activity assay kits (Amersham).
Statistics
Results were expressed as the mean±s.e.m. Statistical comparisons
were made by analysis of variance followed by Scheffe’s post hoc
test. The P-values of o0.05 were considered to be statistically
significant.
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